Related Experiment Videos
Therapeutic targets in radiotherapy
1Division of Radiation Biology, Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305-5152, USA. mbrown@leland.stanford.edu
Background:
Enormous progress has been made in the past 5 years in our understanding of the gene products governing the response of mammalian cells to ionizing radiation. Many of these are potential targets for enhancing the effectiveness of radiotherapy. However, a major barrier to such efforts is the requirement for a preferential effect on tumor vs. normal cells. Such a requirement can only come about by exploiting a known difference between tumor and normal cells.
Methods:
This review highlights three differences between tumor and normal cells that are being exploited with fractionated radiotherapy.
Results:
The three strategies to enhance preferentially tumor response to radiotherapy are inhibition of ras activity using farnesyltransferase inhibitors (FTIs), inhibition of epidermal growth factor receptors (EGFRs), and the use of drugs that preferentially kill hypoxic cells. Each of these strategies exploits a known difference between at least some tumors and their surrounding normal tissues, and each has shown encouraging results when combined with fractionated radiation in preclinical studies.
Conclusions:
For each of the three strategies to enhance preferentially the sensitivity of cancers, the preclinical and early clinical data are promising for their successful application in radiotherapy.
Insights
Researchers are exploring three strategies to improve cancer radiotherapy by targeting differences between tumor and normal cells. These approaches, including inhibiting ras activity, epidermal growth factor receptors, and targeting hypoxic cells, show promise in preclinical studies.
Area of Science:
- Oncology
- Radiation Biology
- Molecular Targeted Therapy
Background:
- Significant advancements in understanding gene products involved in mammalian cell response to ionizing radiation.
- Identification of potential targets for enhancing radiotherapy effectiveness.
- A key challenge in radiotherapy is achieving preferential effects on tumor cells over normal cells, necessitating the exploitation of tumor-specific differences.
Discussion:
- This review focuses on three distinct strategies that leverage known differences between tumor and normal cells to enhance radiotherapy outcomes.
- These strategies are being actively investigated and applied in the context of fractionated radiotherapy.
- Exploiting cellular differences is crucial for improving the therapeutic ratio of radiation treatments.
Key Insights:
- Three promising strategies to preferentially enhance tumor response to radiotherapy include farnesyltransferase inhibitors (FTIs) targeting ras activity, epidermal growth factor receptor (EGFR) inhibitors, and drugs targeting hypoxic cells.
- Each strategy capitalizes on established differences between tumor and normal tissues.
- Preclinical studies combining these strategies with fractionated radiation have yielded encouraging results.
Outlook:
- Preclinical and early clinical data suggest that these three strategies hold significant promise for enhancing cancer treatment efficacy.
- Further research and clinical trials are warranted to fully realize the potential of these targeted approaches in radiotherapy.
- The integration of targeted therapies with radiation offers a path towards more effective and selective cancer treatment.